Four weeks post-injection, X-ray scans were taken and subsequently, excised tibia implanted with tumor cells were subjected to micro-computed tomography (microCT), which showed higher bone loss in the control 22RV1-SCR group compared to DLX1-KO (Fig. 3f and Supplementary Fig 3j). The gene discussed is DLX1; the disease is neoplasm.